The global hormonal replacement therapy market is slated to grow on the basis of increasing prevalence of hormonal disorders coupled with advanced versions of delivery systems available. Hormonal replacement therapy comes into picture when human body is unable to produce hormones in adequate quantity.
It is used to treat male hypogonadism, hypothyroidism, menopause, and growth hormone deficiencies. The symptoms of hormonal imbalance include night sweats, hot flashes, vaginal dryness, low sex-drive, bone loss, burning or itching during intercourse, and others.
The companies operating in the hormone replacement therapy market are exploring the probabilities of deploying hormone replacement therapy for Alzheimer’s, as researchers are stating that administration of this therapy may improve the condition of these patients.
They are also collaborating with healthcare providers to conduct awareness campaigns regarding the vitality of hormone replacement therapy industry.
Hormone replacement therapy is broadly administered for disorders related to menopause, which has resulted in reduction in frequency of hot flashes and risks of osteoporosis. Such therapies are also finding extended applications regarding treatment of thyroid disorders and growth deficiency.
Various lines of treatments are also coming up to cater to pediatric patients contracting growth hormone deficiency. For instance, in August 2021, Ascendis Pharma A/S announced that it had obtained approval from the U.S. FDA for SKYTROFA to treat pediatric patients aged on and above.
However, the higher costs involved with hormone replacement therapy is bound to restrain the hormone replacement therapy market, especially in the low- and middle-income economies.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Menopause is looked upon as a common gynecological disorder in women. On the other hand, growth hormone is a rare endocrine disorder comprising symptoms such as lipid abnormalities, reduced energy levels, resistance against insulin, and less number of physical activities in adults.
The Journal of Clinical Endocrinology & Metabolism states that incidence of growth hormone disorder is higher in patients who suffer from Langerhans cell histiocytosis. This, in turn, promulgates diabetic insipidus, which results in deficiency of growth hormone amongst these patients.
Need to combat the adverse effects of menopause is accelerating the hormone replacement therapy market growth. Along these lines, in September 2021, Theramex announced that it had obtained approval for Bijuva/Bijuve all over the U.K. and the rest of Europe by the regulatory bodies.
Additionally, in December 2020, the Myovant Sciences’ Orgovyx (relugolix) was approved by the U.S. FDA for reducing the quantity of testosterone produced by testicles.
Hormone replacement therapies are available for women contracting menopausal disorders, aged population suffering from hypogonadism, and others in several forms such as buccal patches, tablets, injectables, and others.
Growing adoption of such products around the world is prompting the manufacturers to focus on the development of advanced drug delivery systems such as transdermal estrogen patches and vaginal estrogen drugs.
They are also emphasizing creating awareness about launching low dose estrogen therapy and its benefits over high dose estrogen therapy considering the safety involved. Introducing gel-based formulation for the estrogen patches is another advancement in delivery systems.
Estradiol gel formulation is being prescribed for those who show resistance against oral estrogen therapy. The U.S. FDA has approved estradiol gels for treating menopausal symptom. The percutaneous estradiol gel is simple to apply and has minimal skin reactions.
A drug called Estrasorb has a liposomal formulation, which is applied to skin of the thigh. Moreover, in the U.S., hyfroalcoholic gel is packed in a pump, which delivers 1.25g doses that contain 0.75 mg of 17 beta-estradiol. The advantage of this gel is that it gets easily absorbed into the skin and dries within 2-5 minutes without leaving a single trace of residue.
Continual introduction of advanced delivery system is thus driving the hormone replacement therapy market opportunities.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest hormone replacement therapy market insights, North America dominated the hormonal therapy landscape in 2023 and the scenario is expected to remain unchanged during the forecast period.
This is attributed to rise in the number of patients suffering from growth hormone deficiency disorders and menopause amongst the patients aged 35 and above.
For instance, as per an article published in Medscape in January in 2019, every year close to 6,000 adults are diagnosed with a growth hormone deficiency called hyposomatotropism in the U.S. Besides, new product launches are responsible for contributing toward revenue generation.
For instance, in August 2020, the U.S. FDA approved Novo Nordisk’ Sogroya (somapacitan-beco), a high replacement therapy product.
Europe’s significant hormone replacement therapy market share is due to increase in hormonal disorders in women battling menopausal symptoms and geriatric population contracting hypothyroidism. As per Statistics stated in the Frontier in June 2021, the incidence of thyroid disorders ranges between 0.2 and 5.3% in Europe.
The key players in hormone replacement therapy market are involved in new product launches followed by speedy approvals in order to strengthen their market position. For instance, in May 2021, Myovant Sciences GmbH announced that it had obtained approval from the U.S. FDA for Myfembree, its hormone therapy for uterine fibroid bleeding.
In October 2020, Pfizer Inc., in collaboration with OPKO Health Inc., announced the positive top line results of their Phase 3 trial for investigational long acting hormone, which is since then used as treatment for children suffering from growth hormone deficiency.
Novartis AG, Abbott Laboratories, Mylan N.V., Merck & Co., Inc., Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals Co., Teva Pharmaceutical Industries Ltd., Amgen Inc., Eli, Lilly and Company, Teva Pharmaceutical Industries Ltd., AbbVie Inc., and Noven Pharmaceuticals are some of the key players covered in the hormone replacement therapy market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 21.0 Bn |
| Market Forecast (Value) in 2034 | US$ 38.8 Bn |
| Growth Rate (CAGR) | 5.7% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 21.0 Bn in 2023
It is projected to grow at a CAGR of 5.7% from 2024 to 2034
Growing prevalence of hormonal disorders and launching advanced delivery system
Hospital pharmacies segment accounted for the largest share in 2023
North America was the dominant region in 2023
Novartis AG, Abbott Laboratories, Mylan N.V., Merck & Co., Inc., Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals Co., Teva Pharmaceutical Industries Ltd., Amgen Inc., Eli, Lilly and Company, AbbVie Inc., and Noven Pharmaceuticals
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hormone Replacement Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hormone Replacement Therapy Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Hormone Replacement Therapy Market Analysis and Forecast, by Treatment Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2020-2034
6.3.1. Human Growth Hormone (HGH) Replacement Therapy
6.3.2. Thyroid Replacement Therapy
6.3.3. Testosterone Replacement Therapy
6.3.4. Dopamine Agonist
6.3.5. Somatostatin Analogue
6.3.6. Others (Parathyroid Hormone Replacement Therapy, etc.)
6.4. Market Attractiveness, by Treatment Type
7. Global Hormone Replacement Therapy Market Analysis and Forecast, by Route of Administration
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2020-2034
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Transdermal
7.4. Market Attractiveness, by Route of Administration
8. Global Hormone Replacement Therapy Market Analysis and Forecast, by Disease Indication
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Disease Indication, 2020-2034
8.3.1. Menopause
8.3.2. Hypothyroidism
8.3.3. Male Hypogonadism
8.3.4. Growth Hormone Deficiency
8.3.5. Hypoparathyroidism
8.4. Market Attractiveness, by Disease Indication
9. Global Hormone Replacement Therapy Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Hormone Replacement Therapy Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Hormone Replacement Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2020-2034
11.2.1. Human Growth Hormone (HGH) Replacement Therapy
11.2.2. Thyroid Replacement Therapy
11.2.3. Testosterone Replacement Therapy
11.2.4. Dopamine Agonist
11.2.5. Somatostatin Analogue
11.2.6. Others (Parathyroid Hormone Replacement Therapy, etc.)
11.3. Market Attractiveness, by Treatment Type
11.4. Market Value Forecast, by Route of Administration, 2020-2034
11.4.1. Oral
11.4.2. Parenteral
11.4.3. Transdermal
11.5. Market Attractiveness, by Route of Administration
11.6. Market Value Forecast, by Disease Indication, 2020-2034
11.6.1. Menopause
11.6.2. Hypothyroidism
11.6.3. Male Hypogonadism
11.6.4. Growth Hormone Deficiency
11.6.5. Hypoparathyroidism
11.7. Market Attractiveness, by Disease Indication
11.8. Market Value Forecast, by Distribution Channel, 2020-2034
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Treatment Type
11.11.2. By Route of Administration
11.11.3. By Disease Indication
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Hormone Replacement Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2020-2034
12.2.1. Human Growth Hormone (HGH) Replacement Therapy
12.2.2. Thyroid Replacement Therapy
12.2.3. Testosterone Replacement Therapy
12.2.4. Dopamine Agonist
12.2.5. Somatostatin Analogue
12.2.6. Others (Parathyroid Hormone Replacement Therapy, etc.)
12.3. Market Attractiveness, by Treatment Type
12.4. Market Value Forecast, by Route of Administration, 2020-2034
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Transdermal
12.5. Market Attractiveness, by Route of Administration
12.6. Market Value Forecast, by Disease Indication, 2020-2034
12.6.1. Menopause
12.6.2. Hypothyroidism
12.6.3. Male Hypogonadism
12.6.4. Growth Hormone Deficiency
12.6.5. Hypoparathyroidism
12.7. Market Attractiveness, by Disease Indication
12.8. Market Value Forecast, by Distribution Channel, 2020-2034
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Treatment Type
12.11.2. By Route of Administration
12.11.3. By Disease Indication
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Hormone Replacement Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2020-2034
13.2.1. Human Growth Hormone (HGH) Replacement Therapy
13.2.2. Thyroid Replacement Therapy
13.2.3. Testosterone Replacement Therapy
13.2.4. Dopamine Agonist
13.2.5. Somatostatin Analogue
13.2.6. Others (Parathyroid Hormone Replacement Therapy, etc.)
13.3. Market Attractiveness, by Treatment Type
13.4. Market Value Forecast, by Route of Administration, 2020-2034
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Transdermal
13.5. Market Attractiveness, by Route of Administration
13.6. Market Value Forecast, by Disease Indication, 2020-2034
13.6.1. Menopause
13.6.2. Hypothyroidism
13.6.3. Male Hypogonadism
13.6.4. Growth Hormone Deficiency
13.6.5. Hypoparathyroidism
13.7. Market Attractiveness, by Disease Indication
13.8. Market Value Forecast, by Distribution Channel, 2020-2034
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Treatment Type
13.11.2. By Route of Administration
13.11.3. By Disease Indication
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Hormone Replacement Therapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Type, 2020-2034
14.2.1. Human Growth Hormone (HGH) Replacement Therapy
14.2.2. Thyroid Replacement Therapy
14.2.3. Testosterone Replacement Therapy
14.2.4. Dopamine Agonist
14.2.5. Somatostatin Analogue
14.2.6. Others (Parathyroid Hormone Replacement Therapy, etc.)
14.3. Market Attractiveness, by Treatment Type
14.4. Market Value Forecast, by Route of Administration, 2020-2034
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Transdermal
14.5. Market Attractiveness, by Route of Administration
14.6. Market Value Forecast, by Disease Indication, 2020-2034
14.6.1. Menopause
14.6.2. Hypothyroidism
14.6.3. Male Hypogonadism
14.6.4. Growth Hormone Deficiency
14.6.5. Hypoparathyroidism
14.7. Market Attractiveness, by Disease Indication
14.8. Market Value Forecast, by Distribution Channel, 2020-2034
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Treatment Type
14.11.2. By Route of Administration
14.11.3. By Disease Indication
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Hormone Replacement Therapy Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment Type, 2020-2034
15.2.1. Human Growth Hormone (HGH) Replacement Therapy
15.2.2. Thyroid Replacement Therapy
15.2.3. Testosterone Replacement Therapy
15.2.4. Dopamine Agonist
15.2.5. Somatostatin Analogue
15.2.6. Others (Parathyroid Hormone Replacement Therapy, etc.)
15.3. Market Attractiveness, by Treatment Type
15.4. Market Value Forecast, by Route of Administration, 2020-2034
15.4.1. Oral
15.4.2. Parenteral
15.4.3. Transdermal
15.5. Market Attractiveness, by Route of Administration
15.6. Market Value Forecast, by Disease Indication, 2020-2034
15.6.1. Menopause
15.6.2. Hypothyroidism
15.6.3. Male Hypogonadism
15.6.4. Growth Hormone Deficiency
15.6.5. Hypoparathyroidism
15.7. Market Attractiveness, by Disease Indication
15.8. Market Value Forecast, by Distribution Channel, 2020-2034
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Treatment Type
15.11.2. By Route of Administration
15.11.3. By Disease Indication
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Novartis AG
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Abbott Laboratories
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Mylan N.V.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Merck & Co., Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Bayer AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Pfizer Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Novo Nordisk A/S
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. QuatRx Pharmaceuticals Co.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Teva Pharmaceutical Industries Ltd.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Amgen Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Eli, Lilly and Company
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. AbbVie Inc.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Noven Pharmaceuticals
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview
List of Tables
Table 01: Global Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 02: Global Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 03: Global Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 04: Global Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 05: Global Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 06: North America Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 07: North America Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 08: North America Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 09: North America Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 10: North America Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 11: Europe Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 13: Europe Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 14: Europe Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 15: Europe Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 16: Asia Pacific Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 18: Asia Pacific Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 19: Asia Pacific Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 20: Asia Pacific Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 21: Latin America Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 23: Latin America Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 24: Latin America Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 25: Latin America Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 26: Middle East & Africa Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 28: Middle East & Africa Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 29: Middle East & Africa Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 30: Middle East & Africa Hormone Replacement Therapy Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Hormone Replacement Therapy Market Size (US$ Bn), by Region, 2023 and 2034
Figure 02: Global Hormone Replacement Therapy Market Revenue (US$ Bn), by Treatment Type, 2023
Figure 03: Global Hormone Replacement Therapy Market Value Share, by Treatment Type, 2023
Figure 04: Global Hormone Replacement Therapy Market Revenue (US$ Bn), by Route of Administration, 2023
Figure 05: Global Hormone Replacement Therapy Market Value Share, by Route of Administration, 2023
Figure 06: Global Hormone Replacement Therapy Market Revenue (US$ Bn), by Disease Indication, 2023
Figure 07: Global Hormone Replacement Therapy Market Value Share, by Disease Indication, 2023
Figure 08: Global Hormone Replacement Therapy Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 09: Global Hormone Replacement Therapy Market Value Share, by Distribution Channel, 2023
Figure 10: Global Hormone Replacement Therapy Market Value Share, by Region, 2023
Figure 11: Global Hormone Replacement Therapy Market Value (US$ Bn) Forecast, 2020-2034
Figure 12: Global Hormone Replacement Therapy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 13: Global Hormone Replacement Therapy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 14: Global Hormone Replacement Therapy Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 15: Global Hormone Replacement Therapy Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 16: Global Hormone Replacement Therapy Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 17: Global Hormone Replacement Therapy Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 18: Global Hormone Replacement Therapy Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 19: Global Hormone Replacement Therapy Market Value Share, by Distribution Channel, 2023
Figure 20: Global Hormone Replacement Therapy Market Value Share Analysis, by Region, 2023 and 2034
Figure 21: Global Hormone Replacement Therapy Market Attractiveness Analysis, by Region, 2024-2034
Figure 22: North America Hormone Replacement Therapy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 23: North America Hormone Replacement Therapy Market Attractiveness Analysis, by Country, 2024-2034
Figure 24: North America Hormone Replacement Therapy Market Value Share Analysis, by Country, 2023 and 2034
Figure 25: North America Hormone Replacement Therapy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 26: North America Hormone Replacement Therapy Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 27: North America Hormone Replacement Therapy Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 28: North America Hormone Replacement Therapy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 29: North America Hormone Replacement Therapy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 30: North America Hormone Replacement Therapy Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 31: North America Hormone Replacement Therapy Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 32: North America Hormone Replacement Therapy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 33: Europe Hormone Replacement Therapy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 34: Europe Hormone Replacement Therapy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 35: Europe Hormone Replacement Therapy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 36: Europe Hormone Replacement Therapy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 37: Europe Hormone Replacement Therapy Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 38: Europe Hormone Replacement Therapy Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 39: Europe Hormone Replacement Therapy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 40: Europe Hormone Replacement Therapy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 41: Europe Hormone Replacement Therapy Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 42: Europe Hormone Replacement Therapy Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 43: Europe Hormone Replacement Therapy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 44: Asia Pacific Hormone Replacement Therapy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 45: Asia Pacific Hormone Replacement Therapy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 46: Asia Pacific Hormone Replacement Therapy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 47: Asia Pacific Hormone Replacement Therapy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 48: Asia Pacific Hormone Replacement Therapy Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 49: Asia Pacific Hormone Replacement Therapy Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 50: Asia Pacific Hormone Replacement Therapy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 51: Asia Pacific Hormone Replacement Therapy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 52: Asia Pacific Hormone Replacement Therapy Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 53: Asia Pacific Hormone Replacement Therapy Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 54: Asia Pacific Hormone Replacement Therapy Market Attractiveness Analysis, by Distribution Channel, 2023-2034
Figure 55: Latin America Hormone Replacement Therapy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 56: Latin America Hormone Replacement Therapy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 57: Latin America Hormone Replacement Therapy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 58: Latin America Hormone Replacement Therapy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 59: Latin America Hormone Replacement Therapy Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 60: Latin America Hormone Replacement Therapy Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 61: Latin America Hormone Replacement Therapy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 62: Latin America Hormone Replacement Therapy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 63: Latin America Hormone Replacement Therapy Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 64: Latin America Hormone Replacement Therapy Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 65: Latin America Hormone Replacement Therapy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 66: Middle East & Africa Hormone Replacement Therapy Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 67: Middle East & Africa Hormone Replacement Therapy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 68: Middle East & Africa Hormone Replacement Therapy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 69: Middle East & Africa Hormone Replacement Therapy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 70: Middle East & Africa Hormone Replacement Therapy Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 71: Middle East & Africa Hormone Replacement Therapy Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 72: Middle East & Africa Hormone Replacement Therapy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 73: Middle East & Africa Hormone Replacement Therapy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 74: Middle East & Africa Hormone Replacement Therapy Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 75: Middle East & Africa Hormone Replacement Therapy Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 76: Middle East & Africa Hormone Replacement Therapy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Hormone Replacement Therapy Market
